Shalby Limited
Shalby Limited operates in Hospital, part of the Healthcare sector. It booked ₹331 cr of revenue in its latest quarter (Q1 FY27) and kept 3.3% of sales as profit.
| Segment | FY25 | FY26 | Share |
|---|---|---|---|
| Healthcare Services | 980 | 1,010 | 90% → 88% |
| Manufacturing & Trading of Implants | — | — | — |
| Manufacturing of Implants | 107 | 131 | 10% → 12% |
| Total | 1,087 | 1,141 |
From the company's consolidated segment filings (Ind AS 108). Margin is segment operating profit (before interest & tax) over segment revenue; reconciliation rows like inter-segment eliminations are excluded from the mix.
“Shalby Limited (“Shalby” or “the milestone of 1.75 lakh procedures to The Company is also making Company”) is one of India’s foremost date.”
“is to provide world-class healthcare education that combines theoretical knowledge with practical clinical exposure, ensuring our graduates are industry-ready and equipped to meet the evolving demands of the healthcare sector.”
Healthier than 39% of companies in Healthcare, on all six measures of filed financials. Each measure is ranked against the 81–150 companies that reported it.
Measures financial condition, not whether to buy. Learn what this score means · How this is calculated
- RSI (14)
- 26
At close. Not part of the score.
How much profit it earns on the money it employs
How much it owes, and whether earnings cover the interest
Whether reported profit actually arrives as cash
Whether sales and profit have grown, and how steadily
What today's price implies, against our models or its peers
How much of the promoters' stake is pledged, and how much they hold · highest in its sector on what we could measure
What if I invest in SHALBY?
Set a growth rate and see what a monthly SIP would add up to. Your assumption, our arithmetic.
The starting rate is a round number, not a view on this company — this is your assumption, and the figure above is arithmetic on it. Returns are not steady year to year, and a real holding would not grow in a straight line. We do not publish price targets or predict returns.
P/E, ROE, ROCE and margins are annualised from the latest quarter; per-share and balance-sheet ratios use the most recent balance sheet on file · prices as of 2026-09-17.
An educational model from the company's own filings, every assumption shown — not investment advice or a price target. Prices can stay above or below any model for years.
| Revenue from Operations | ₹331 cr |
| Other Income | ₹7 cr |
| Total Income | ₹339 cr |
| Cost of Materials | ₹8 cr |
| Purchases of Stock-in-Trade | ₹42 cr |
| Inventory Change (±) | ₹13 cr |
| Employee Benefit Expense | ₹48 cr |
| Finance Costs | ₹11 cr |
| Depreciation & Amortisation | ₹19 cr |
| Other Expenses | ₹178 cr |
| Total Expenses | ₹319 cr |
| Profit before Tax | ₹20 cr |
| Tax Expense | ₹9 cr |
| Net Profit | ₹10 cr |
| Net margin on total income | 3.1% |
| Metric | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|
| Revenue | 272 cr | 287 cr | 331 cr |
| Total income | 279 cr | 296 cr | 339 cr |
| Expenses | 270 cr | 286 cr | 319 cr |
| Profit before tax | 9 cr | 10 cr | 20 cr |
| Tax | 8 cr | -9 cr | 9 cr |
| Net profit (owners' share) | 2 cr | 18 cr | 11 cr |
| Net margin (owners' share, on revenue) | 0.6% | 6.4% | 3.3% |
| EPS (₹) | 0.12 | 1.72 | 0.98 |
| Company | Price | Market cap | P/E | ROE | Net margin | 1-yr return |
|---|---|---|---|---|---|---|
| Apollo Hospitals Enterprise Limited | ₹8,769 | ₹1.26 L cr | 54.3 | 24.5% | 8.2% | — |
| Max Healthcare Institute Limited | ₹1,037 | ₹1.01 L cr | 78.1 | 12.0% | 13.6% | — |
| Manipal Health Enterprises Limited | ₹722 | ₹85,125 cr | 92.0 | — | 7.5% | — |
| Fortis Healthcare Limited | ₹886 | ₹66,897 cr | 62.8 | 10.8% | 10.5% | — |
| Aster DM Quality Care Limited | ₹761 | ₹39,412 cr | 613.4 | 1.4% | 1.2% | — |
| Global Health Limited | ₹1,424 | ₹38,273 cr | 60.2 | 16.0% | 12.2% | — |
| Narayana Hrudayalaya Ltd. | ₹1,869 | ₹38,187 cr | 45.8 | 18.3% | 7.7% | — |
| Krishna Institute of Medical Sciences Limited | ₹792 | ₹33,258 cr | 190.3 | 7.4% | 3.5% | — |
| Dr. Agarwal's Health Care Limited | ₹500 | ₹15,855 cr | 87.4 | 8.9% | 7.4% | — |
| Action | Detail | Ex-date |
|---|---|---|
| Dividend | ₹1.2 / share | 19 Sep 2024 |
| Dividend | ₹1.2 / share | 8 Aug 2023 |
| Dividend | ₹1 / share | 19 Sep 2022 |
| Dividend | ₹1 / share | 17 Sep 2021 |
| Dividend | ₹0.5 / share | 4 Sep 2020 |
| Dividend | ₹0.5 / share | 16 Aug 2019 |
A company cannot decide everything on its own. Things like a top executive’s pay, issuing new shares, or re-appointing a director have to be put to the people who own the company, and they vote — one vote per share. So whoever owns the most shares has the most say.
Every vote count above is taken from the result the company filed with the stock exchange, certified by an independent counter. To work out what would have happened without the promoters, we simply remove their votes and re-apply the same legal bar the proposal had to clear. Nothing here is an estimate or an opinion.
Most Indian companies are controlled by a family or group — the promoters. The exchange requires them to be listed by name, including members who own no shares at all, and requires the company to disclose any business it does with them.
The company also transacted with 14 other related parties — subsidiaries, joint ventures, directors and others — that we could not match by name to the promoter list above. Some may still be connected to the family; we only count the ones the filings let us match with certainty.
Names and holdings from the company’s shareholding pattern filed with the exchange; transactions from the related-party note in its annual report. Every figure is as filed — these are legal, disclosed dealings, and what to make of them is your call.